FIG. 5.
Comparison of total and SIV envelope-specific antibody levels in saliva collected from 16 SIVMac251-infected rhesus macaque saliva at various time points over the course of disease to SIV-inhibitory capacity in vitro. (A) The average percent inhibition of SIVMac239-Cl3env infection by all saliva samples over time. Salivary antibody levels in each saliva sample were measured by ELISA, and total IgG and IgA levels in saliva (B) and SIVgp130 IgG (binding antibody) levels in saliva (C) are shown for select time points over the disease course. Changes in antibody levels were assessed for statistical significance by the Mann–Whitney U test; (†) p < 0.01.